Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature.

Wallace KL, Filipek RL, La Hoz RM, Williamson JC.

J Clin Pharm Ther. 2016 Aug;41(4):441-443. doi: 10.1111/jcpt.12401. Epub 2016 May 20.

PMID:
27207573
2.

Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia.

Biehle LR, Cottreau JM, Thompson DJ, Filipek RL, O'Donnell JN, Lasco TM, Mahoney MV, Hirsch EB.

PLoS One. 2015 Nov 30;10(11):e0143845. doi: 10.1371/journal.pone.0143845. eCollection 2015.

3.

Neutral-carrier ion-selective electrodes assessed by the Nernst-Planck-Poisson model.

Jasielec JJ, Sokalski T, Filipek R, Lewenstam A.

Anal Chem. 2015 Sep 1;87(17):8665-72. doi: 10.1021/acs.analchem.5b00065. Epub 2015 Aug 18.

PMID:
26241734
4.

Crystallization of the photosystem II core complex and its chlorophyll binding subunit CP43 from transplastomic plants of Nicotiana tabacum.

Piano D, El Alaoui S, Korza HJ, Filipek R, Sabala I, Haniewicz P, Buechel C, De Sanctis D, Bochtler M.

Photosynth Res. 2010 Dec;106(3):221-6. doi: 10.1007/s11120-010-9597-x. Epub 2010 Nov 10.

5.

Crystal structure and mechanism of the Staphylococcus cohnii virginiamycin B lyase (Vgb).

Lipka M, Filipek R, Bochtler M.

Biochemistry. 2008 Apr 8;47(14):4257-65. doi: 10.1021/bi7015266. Epub 2008 Mar 15.

PMID:
18341294
6.

NMR assignment of a structurally uncharacterised fragment of recombinant mouse ubiquitin-activating enzyme.

Jaremko L, Jaremko M, Filipek R, Wojciechowski M, Szczepanowski RH, Bochtler M, Zhukov I.

J Biomol NMR. 2006;36 Suppl 1:43. No abstract available.

PMID:
16738783
7.

Fighting an enemy within: cytoplasmic inhibitors of bacterial cysteine proteases.

Potempa J, Golonka E, Filipek R, Shaw LN.

Mol Microbiol. 2005 Aug;57(3):605-10.

8.

Crystal structure of a fragment of mouse ubiquitin-activating enzyme.

Szczepanowski RH, Filipek R, Bochtler M.

J Biol Chem. 2005 Jun 10;280(23):22006-11. Epub 2005 Mar 16.

9.

A comparison of staphostatin B with standard mechanism serine protease inhibitors.

Filipek R, Potempa J, Bochtler M.

J Biol Chem. 2005 Apr 15;280(15):14669-74. Epub 2005 Jan 11.

10.

Genetic characterization of staphopain genes in Staphylococcus aureus.

Golonka E, Filipek R, Sabat A, Sinczak A, Potempa J.

Biol Chem. 2004 Nov;385(11):1059-67.

PMID:
15576326
11.

Prostaphopain B structure: a comparison of proregion-mediated and staphostatin-mediated protease inhibition.

Filipek R, Szczepanowski R, Sabat A, Potempa J, Bochtler M.

Biochemistry. 2004 Nov 9;43(44):14306-15.

PMID:
15518582
12.

Staphostatins resemble lipocalins, not cystatins in fold.

Rzychon M, Filipek R, Sabat A, Kosowska K, Dubin A, Potempa J, Bochtler M.

Protein Sci. 2003 Oct;12(10):2252-6.

13.

The Staphostatin-staphopain complex: a forward binding inhibitor in complex with its target cysteine protease.

Filipek R, Rzychon M, Oleksy A, Gruca M, Dubin A, Potempa J, Bochtler M.

J Biol Chem. 2003 Oct 17;278(42):40959-66. Epub 2003 Jul 21.

14.

New method for typing Staphylococcus aureus strains: multiple-locus variable-number tandem repeat analysis of polymorphism and genetic relationships of clinical isolates.

Sabat A, Krzyszton-Russjan J, Strzalka W, Filipek R, Kosowska K, Hryniewicz W, Travis J, Potempa J.

J Clin Microbiol. 2003 Apr;41(4):1801-4.

15.

Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.

Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF.

J Clin Pharmacol. 2000 Jun;40(6):634-40.

PMID:
10868314

Supplemental Content

Loading ...
Support Center